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QUANTIFYING ANTI-CYTOMEGALOVIRUS (CMV) IMMUNITY WITH CMV
ANTIGEN SPECIFIC T CELLS (CASTS) AFTER ALLOGENEIC HEMATOPOI-
ETIC CELL TRANSPLANT (ALLOHCT)
Chen, G.1, Hahn, T.1, Zhang, Y.1, Pan, D.1, Brix, L.2, Ross, M.1,
Liu, H.1, Wallace, P.1, McCarthy, P.1 1Roswell Park Cancer Institute,
Buffalo, NY; 2 Immudex, Copenhagen, Denmark
Reconstitution of CASTs after alloHCT has previously been
quantified using CMV tetramers. We developed an assay for quanti-
fying CASTs using CMV specific MHC multimers (Dextramers,
Immudex, Denmark). CMVDextramers consist of dextran polymers
conjugated to optimized numbers of MHC-CMV peptide and fluo-
rochrome molecules allowing higher avidity binding to CMV spe-
cific T cells. Dextramers were restricted to HLA-A01, -A02, -A03,
-A24 -B07, -B08, and -B35, and were informative in 93% of our pre-
dominantly White (94%) population. Patient blood samples were
prospectively collected pre-alloHCT and day +30, 100, and 365,
and analyzed by flow cytometry for CASTs with CMV Dextramers.
More than 300 CMVDextramer measurements from 89 consecutive
alloHCT patients treated from 2005 - 2011 with. 1 post-alloHCT
CAST measurement were analyzed. CMV reactivation was defined
as the presence of CMV antigen on . 2/50,000 cells, . 1/100,000
cells twice consecutively, or . 1/100,000 cells followed by pre-
emptive CMV therapy. Absence of CMV reactivation was defined
as 0 cells or 1/100,000 cells positive for CMV no more than once
with no anti-CMV treatment. 30/89 (34%) patients reactivated
CMV a median of 40 days (range 23-341) post-alloHCT. None of
37 recipients with undetectable CASTs before allo-HCT reactivated
CMV by day +30 vs. 10/52 (19%) of recipients with detectable
CASTs (p 5 0.005), recapitulating CMV reactivation patterns seen
in recipients with positive CMV serologies. We correlated the num-
ber of CASTs with recipient and donor CMV serology as a surrogate
for anti-CMV immunity. In samples with CD3+ T cells $ 400/mL,
CASTs correlated with recipient CMV serology with 67% sensitiv-
ity and 90% specificity (see Table). Sensitivity may have been lower
than expected due to decreased anti-CMV IgG production second-
ary to chemotherapy and/or increased granularity of flow cytometry
measurements for CASTs. In another analysis, CASTs at day +30
corresponded to positive CMV donor, but not recipient, serology,
and not with CMV reactivation up to day +30, suggesting that the
adoptive transfer of CASTs occurs with alloHCT. Preliminary anal-
yses confirm prior reports of decreased relapse of underlying cancers
after CMV reactivation. Our study suggests that Dextramers may be
used to monitor reconstitution of CMV immunity post-alloHCT,
that they may be a more sensitive test than CMV serology, and
that adoptive transfer of anti-CMV immunity can be quantified.
Table 1. Correlation of CASTs and CMV Serology
Pre-alloHCT Recipient CMV SerologyPre-alloHCT CASTs N (row)Negative (N 5 32) Positive (N 5 31)Undetectable 18 (56%) 2 (6%) 20
Detectable 14 (44%) 29 (94%) 43*All samples with $400 CD3+ T cells191
SAFETY AND PERSISTENCE OF INFUSED CD19-CAR-MODIFIED
MULTIVIRUS SPECIFIC CTLS IN B CELL MALIGNANCIES POST
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Cruz, C.R.Y.1,Micklethwaite, K.P.1, Savoldo, B.1, Ku, S.1, Krance, R.A.1,
Diouf, O.1, Kamble, R.1, Kennedy-Nasser, A.1, Barrett, A.J.2,
Shpall, E.J.3, Heslop, H.E.1, Rooney, C.M.1, Brenner, M.K.1,
Bollard, C.M.1, Dotti, G.1 1Baylor College of Medicine, The Methodist
Hospital, Texas Children’s Hospital, Houston, TX; 2National Institutes
of Health, Bethesda,MD; 3The University of Texas MDAnderson Cancer
Center, Houston, TX
Allogeneic hematopoietic stem cell transplant (HSCT) may in-
crease disease-free survival in patients with high-risk B-cell malig-nancies, but delayed immune reconstitution is associated with viral
infections and disease relapse. We reasoned that a single T-cell plat-
form mediating antiviral and antileukemic activity may benefit these
patients. We prepared CTLs with native specificities directed to-
wards EBV/CMV/adv, then engineered them to express chimeric
antigen receptors (CAR) targeting CD19. We used donor-derived
antigen presenting cells expressing adenovirus antigens & transgenic
CMVpp65. After 3 stimulations, multivirus-specific CTL were
transduced with a retroviral vector encoding CAR-CD19.
Safety: 4 patients (2 relapsed ALL, 2 B-CLL) were infused with 1.5-
3x107 cells/m2 without infusion related toxicity. Patient 2 developed
fever, diarrhea and hypotension 4 weeks post T cells; findings were
consistent with ileitis at a previous site of disease. Gut biopsy showed
abnormal absence of normal & malignant B cells, but significant
levels of CAR-CD19 T cells by qPCR.
Persistence:There was a predictable decline of T cells in peripheral
blood following infusion (undetectable in 1-4 weeks). However, per-
sistence up to 9 weeks after T cell administration is documented by
their presence in disease sites like the gastrointestinal tract (patient 2,
4 weeks post CTL) and the bone marrow (patient 1 and 3, 9 & 4
weeks post CTL respectively).
Anti-tumor activity: Patient 1 (Ph+ ALL) had 4% blasts in the pe-
ripheral blood at time of CTL infusion #1 which cleared within 2
weeks. She received a 2nd infusion 2 months later. She became
bcr-abl-negative but subsequently relapsed and died of progressive
disease 7 months post CTL. Patient 2 with CLL had resolution of
lymphadenopathy within 2 weeks but, following disappearance of
CTLs from peripheral blood, showed evidence of disease progres-
sion 2 months post CTL and died weeks after. Patient 3 with CLL
has had stable disease. Patient 4 (relapsed ALL) responded to the first
CTL infusion with a decrease of blasts (0.5% to 0.3%) 4 days post
CTL. He presented 2 weeks later with 4% blasts, requiring a 2nd
dose of CTLs which decreased disease to 0.2% 2 days post-infusion.
Anti-viral activity:No patient developed viral infections post CTL.
These early results provide evidence of the safety, persistence, and
effectiveness of monoculture CD19CAR trivirus T cells in the treat-
ment of high risk B-cell malignancies post HSCT.192
LONGITUDINAL MONITORING OF IMMUNE RECONSTITUTION AFTER
ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
(PBSCT): IMPACT OF T-CELL DEPLETION OF THE GRAFT
Servais, S.1,2, Hannon, M.2, Daulne, C.2, Gothot, A.1,2, Yves, B.1,2,
Baron, F.1,2 1CHU of Liege, Liege, Belgium; 2University of Liege, Liege,
Belgium
Background: T cell depletion by positive selection of CD34+ cells
of the graft is an effective procedure to reduce the incidence of
graft-versus-host disease following allogeneic PBSCT. However, it
has been suggested that it might impact immune reconstitution.
Patients andMethods:We retrospectively compared the kinetics of
recovery of T, B and NK- cells compartments in 108 adult patients
who had undergone allogeneic PBSCT after high dose conditioning.
Patients had received either CD34-selected (CD34 group, n5 62) or
unmanipulated PBSCT (PBSC group, n5 46). In the CD34 group,
43 of 62 patients had received pre-emptive CD8-depleted donor
lymphocyte infusions (DLI) starting at days 40-60 after PBSCT in
an effort to prevent disease relapse. Circulating cell phenotypes
were studied by flow cytometry on days 28, 40, 60, 80, 100, 180
and 365 after PBSCT, and then yearly thereafter. Median follow-
up was 6 months for both groups (ranging from 1 to 60 months).
We also monitored T-cell repertoire reconstitution on days 100
and 365 post-PBSCT using third complementary region (CDR3)
size spectratyping method (in 9 and 13 patients on days 100 and 2
and 7 patients on days 365, for CD34 andPBSCgroups respectively).
Results: Normal levels of NK (CD3- CD56+) cells and CD8+
(CD3+ CD8+) T cells were reached one month after PBSCT and
were similar in CD34 and PBSC patients. B cell counts attained
lower limit of normal values six months after PBSCT and were sim-
ilar in the CD34 and PBSC groups. CD4+ T-cell reconstitution was
slow in the two groups of patients, with normal values reached only
after 18 to 24 months post-PBSCT. The number of naive CD4+ T
cells (CD4+ CD45RA+) was particularly low throughout the first
